Please login to the form below
Myalept
This page shows the latest Myalept news and features for those working in and with pharma, biotech and healthcare.
R&D productivity takes off
For example, Amgen's Blincyto (blinatumomab) for a rare form of leukaemia has been priced at $178, 000 a year, while AZ's Myalept (metreleptin) for the ultra-rare metabolic disorder
Latest news
-
Nexium windfall lifts AZ in third quarter
Meanwhile, AZ also said it is selling Myalept (metreleptin), an approved drug for generalised lipodystrophy, to Aegerion Pharmaceuticals. ... The latter will pay $325m upfront to acquire the global rights to Myalept, subject to an existing distributor
-
FDA approves AZ’s fish oil drug
Epanova gets green light to reduce high levels of fat in the blood
-
AZ gets limited approval for metreleptin in US
First FDA-backed treatment for rare disease lipodystrophy. AstraZeneca's Myalept has become the first approved treatment for the rare disease lipodystrophy after getting a green light from the FDA. ... Myalept will be "a much-needed treatment option for
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
- Senior Content Editor - Biotechnology
-
Salary TBC
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
- Saturnino Izquierdo takes on expanded role at McCann Health
- J&J delays EU COVID-19 vaccine rollout following pause in the US
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- UK trial evaluating mixed-vaccine regimens includes two more jabs
- Follow the user – democratising medical conference design
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- How a design mindset can lead to better medical outcomes
- By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
- How does the government plan to reshape the NHS?
- Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
- Want to give perfect client service? Tough luck, you’re human
- In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
Quick links
Infographics
